At House Drug Pricing Hearing, ASHP Targets DIR Fees, Anti-Competition Strategies

By David Wild
In a statement submitted to the U.S. House Energy and Commerce Subcommittee on Health as part of a hearing held today on high drug prices, ASHP took aim at several features of the drug supply chain it believes are keeping prices high.